Press release
Graft versus host disease Pipeline Report 2023: Treatment Drugs, Emerging Therapies with Over 60 Key Companies Working in the Domain by DelveInsight | Biocon, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, R
Graft versus host disease Pipeline
DelveInsight's "Graft versus host disease Pipeline Insight - 2023" report provides comprehensive global coverage of available, marketed, and pipeline GVHD therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Graft versus host disease pipeline domain.
Request for sample page: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Graft versus host disease Pipeline Report
• DelveInsight's Graft versus host disease pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Graft versus host disease treatment.
• Leading Graft versus host disease (GVHD) companies such as Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others are evaluating new drugs for GVHD to improve the treatment landscape.
• Promising Graft versus host disease pipeline therapies in various stages of development include ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.
Graft versus host disease Overview
Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient's body cells. "Graft" refers to transplanted, or donated tissue, and "host" refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT).
Find out more about Graft versus host disease treatment drugs @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Graft versus host disease Pipeline Drugs:
• Itolizumab: Biocon
• T-Guard: Xenikos
• MaaT013: MaaT Pharma
• Axatilimab: Syndax Pharmaceuticals
• TQ 05105: Chia Tai Tianqing Pharmaceutical Group
• And Many Others
Graft versus host disease Therapeutics Assessment
The Graft versus host disease pipeline report proffers an integral view of GVHD emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Graft versus host disease pipeline therapies @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Graft versus host disease Pipeline Report
• Coverage: Global
• GVHD Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• GVHD Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Graft versus host disease Therapeutics Assessment By Route of Administration: Intravenous, Oral, Rectal.
• Key GVHD Companies: Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others
• Key GVHD Pipeline Therapies: ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.
Dive deep into rich insights for new drugs for GVHD treatment; visit @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
• Introduction
• Executive Summary
• Graft versus host disease (GVHD): Overview
• What is Graft versus host disease (GVHD)?
• Types of Graft versus host disease (GVHD)
• Causes
• Epidemiology and Risk Factors
• Disease Management
• GVHD Pipeline Therapeutics
• Comparative Analysis
• Graft versus host disease Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
• Graft versus host disease (GVHD)- DelveInsight's Analytical Perspective
• Late Stage Products (Preregistration)
• Comparative Analysis
• Itolizumab: Biocon
• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report…..
• Mid Stage Products (Phase II)
• Comparative Analysis
• ASC930: ASC Therapeutics
• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report…..
• Early Stage Products (Phase I/II)
• TQ 05105: Chia Tai Tianqing Pharmaceutical Group
• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report…..
• Early Stage Products (Phase I)
• Comparative Analysis
• Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report…..
• Inactive Products
• Comparative Analysis
• Graft versus host disease (GVHD) Key Companies
• Graft versus host disease (GVHD) Key Products
• Graft versus host disease (GVHD) Unmet Needs
• Graft versus host disease (GVHD) Market Drivers and Barriers
• Graft versus host disease (GVHD) Future Perspectives and Conclusion
• Graft versus host disease (GVHD) Analyst Views
• Appendix
Trending Reports:
• Menorrhalgia Market - https://www.delveinsight.com/report-store/menorrhalgia-market
• Complicated Intra-Abdominal Infections market - https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market
• Bronchial Spasm Market - https://www.delveinsight.com/report-store/bronchial-spasm-market
• Acute Radiation Syndrome Market - https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Age Related Vision Dysfunction Market - https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market
• Cerebral Aneurysm Market - https://www.delveinsight.com/report-store/cerebral-aneurysm-market
• Severe Hypoglycemia Market - https://www.delveinsight.com/report-store/severe-hypoglycemia-market
• Ada-Scid Competitive Landscape - https://www.delveinsight.com/report-store/ada-scid-competitive-landscape-and-market-insight
• DCSSC Market - https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market
• Bradykinesia Market - https://www.delveinsight.com/report-store/bradykinesia-market
Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graft versus host disease Pipeline Report 2023: Treatment Drugs, Emerging Therapies with Over 60 Key Companies Working in the Domain by DelveInsight | Biocon, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, R here
News-ID: 3019171 • Views: …
More Releases from DelveInsight Business Research
Wiskott-Aldrich Syndrome Clinical Trial Outlook: 5+ Active Players, 5+ Pipeline …
DelveInsight's "Wiskott-Aldrich Syndrome Pipeline Insight" report offers in-depth coverage of more than five companies and over five drug candidates currently shaping the Wiskott-Aldrich Syndrome (WAS) pipeline landscape. The report presents detailed profiles of pipeline therapies spanning both clinical and preclinical stages. It further evaluates therapeutic candidates based on product category, development stage, route of administration, and molecular class, while also identifying inactive or discontinued assets within the pipeline.
Explore the newest…
Dilated Cardiomyopathy Drug Development Outlook 2025: 8+ Active Players and 8+ P …
DelveInsight's "Dilated Cardiomyopathy Pipeline Insight" report offers in-depth analysis of more than 8 companies and 8 pipeline candidates shaping the Dilated Cardiomyopathy (DCM) development landscape.
The report presents detailed profiles of pipeline drugs across both clinical and preclinical stages. It also evaluates the DCM therapeutic landscape based on product classification, development phase, route of administration, and molecule category. In addition, the report identifies discontinued and inactive assets within this therapeutic area.
Explore…
Adult T-Cell Leukemia-Lymphoma Market Outlook 2034: Epidemiology Shifts, Emergin …
DelveInsight's "Adult T-Cell Leukemia-Lymphoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers a comprehensive analysis of Adult T-Cell Leukemia-Lymphoma (ATLL), covering both historical and projected epidemiology along with evolving market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
This latest healthcare market forecast provides a detailed evaluation of Adult T-Cell Leukemia-Lymphoma, presenting extensive insights into revenue patterns, disease prevalence, and the current treatment…
Hypopituitarism Market: Investment-Ready Growth Trends to 2034 - DelveInsight
DelveInsight's "Hypopituitarism Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hypopituitarism, historical and forecasted epidemiology as well as the Hypopituitarism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hypopituitarism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypopituitarism Market Forecast
https://www.delveinsight.com/sample-request/hypopituitarism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Hypopituitarism Market Report:…
More Releases for Graft
Bone Graft and Graft Substitute Market Latest Research, Top Impacting Factors, G …
The "Bone Graft and Graft Substitute Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. A bone graft is a surgical treatment used to repair problems with bones or joints. Bone grafting, or transplanting of bone tissue, is useful in fixing bones that are impaired from trauma or problem joints. Bone growth around an embedded…
Synthetic Bioactive Bone Graft Substitutes Market Growing need for bone graft su …
Global Synthetic Bioactive Bone Graft Substitutes Market Overview:
The Synthetic Bioactive Bone Graft Substitutes market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Synthetic Bioactive Bone Graft Substitutes market has experienced significant growth, driven by factors such as increasing consumer demand,…
Bone Graft Substitutes Market Size to Hit $3.8 Billion by 2028 | Bone Graft Subs …
Market Overview:
According to our experience research team, Bone Graft Substitutes Market was valued at USD 2.7 Billion in 2021, and the global Bone Graft Substitutes industry is projected to reach a value of USD 3.8 Billion by 2028, at a CAGR of 5.9% during the forecast period 2022-2028
Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology,…
Graft Delivery Devices Market Facts, Figures and Analytical Insights, 2017 to 20 …
Global Graft Delivery Devices Market: Snapshot
Graft delivery relates to the surgically transplantation of a piece of living tissues and the procedure can be highly essential as well as complex at the same time. Consequently, technological advancements have paved way to graft delivery devices that can minimally breach bone, fat, and vascular parts of the body to transfer drugs during plastic and reconstructive surgeries as well as arthroscopic and orthopedic surgeries.…
Glass Graft Polyols Market 2019| BASF SE, Sinopec, Shell, Oltchim, The Dow Chemi …
Market Research Hub (MRH) has actively included a new research study titled “Global Graft Polyols Market” Research Report 2019 to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until forecast period limit; 2025. In…
Global Vascular Graft Market Growth Analysis Report 2018-2025Global Vascular Gra …
Research Report 2018-2025 on "Global Vascular Graft Market" which provides an outlook of current market value of Vascular Graft Market as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% in Vascular Graft Market by the end of 2025. The report on the global Vascular Graft market uses the top-down and bottom-up approaches to define, analyze, and describe the Vascular Graft market 2018 trends…
